[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hospital Acquired Pneumonia (HAP) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 80 pages | ID: H9C6722C3D98EN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Hospital Acquired Pneumonia (HAP) Drug pipeline report- 2020 is an annual R&D review of Hospital Acquired Pneumonia (HAP) pipeline candidates. The report presents the current status of all major Hospital Acquired Pneumonia (HAP) therapeutic compounds. Detailed insights into Hospital Acquired Pneumonia (HAP) pipeline development, current status, companies, drug profiles and Hospital Acquired Pneumonia (HAP) preclinical and clinical trials are included.

2020 Hospital Acquired Pneumonia (HAP) Pipeline Market Insights
Hospital Acquired Pneumonia (HAP) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Hospital Acquired Pneumonia (HAP) therapies, pipeline by phase and others are included.

Hospital Acquired Pneumonia (HAP) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Hospital Acquired Pneumonia (HAP) Therapeutic Drug candidates
Both active and inactive Hospital Acquired Pneumonia (HAP) pipeline drug candidates are included in the report

Hospital Acquired Pneumonia (HAP) Clinical Trials and preclinical Studies
Hospital Acquired Pneumonia (HAP) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Hospital Acquired Pneumonia (HAP) pipeline market developments
Hospital Acquired Pneumonia (HAP) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Hospital Acquired Pneumonia (HAP) pipeline companies in active development
The report analyzes Hospital Acquired Pneumonia (HAP) pipeline of the below companies-

Aridis Pharmaceuticals Inc, AstraZeneca Plc, Biolytx Pharmaceuticals Corp, Centauri Therapeutics Ltd, Cumberland Pharmaceuticals Inc, Destiny Pharma Ltd, Dong-A Socio Holdings Co Ltd, EnBiotix Inc, Evaxion Biotech ApS, MedImmune LLC, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Motif Bio Plc, Nabriva Therapeutics plc, Peptineo, Polyphor AG, Sealife PHARMA GMBH, Shionogi & Co Ltd, Spero Therapeutics Inc, Tetraphase Pharmaceuticals Inc, TGV Laboratories Inc, Wockhardt Ltd

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
22 Companies investing in Hospital Acquired Pneumonia (HAP) pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Hospital Acquired Pneumonia (HAP) pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. HOSPITAL ACQUIRED PNEUMONIA (HAP) PIPELINE MARKET INSIGHTS, 2020

1.1 Hospital Acquired Pneumonia (HAP) Disease Overview
1.2 Hospital Acquired Pneumonia (HAP) Drug Pipeline Snapshot, 2020
  1.2.1 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Phase
  1.2.2 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Company
  1.2.3 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Mechanism of Action
  1.2.4 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Route of Administration

2. HOSPITAL ACQUIRED PNEUMONIA (HAP) COMPANY WISE PIPELINE DETAILS

Aridis Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
AstraZeneca Plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Biolytx Pharmaceuticals Corp Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Centauri Therapeutics Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Cumberland Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Destiny Pharma Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Dong-A Socio Holdings Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
EnBiotix Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Evaxion Biotech ApS Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
MedImmune LLC Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Meiji Seika Pharma Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Merck & Co Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Motif Bio Plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Nabriva Therapeutics plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Peptineo Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Polyphor AG Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sealife PHARMA GMBH Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Shionogi & Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Spero Therapeutics Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tetraphase Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
TGV Laboratories Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Wockhardt Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. HOSPITAL ACQUIRED PNEUMONIA (HAP) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. HOSPITAL ACQUIRED PNEUMONIA (HAP) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications